Millions of people across the UK living with dangerously high cholesterol now have access to a promising new treatment on the NHS, following approval from the National Institute for Health and Care Excellence (NICE). The drug – a combination of ezetimibe and bempedoic acid, marketed as Nexletol or Nilemdo – offers fresh hope for adults who haven't been able to control their cholesterol levels with existing treatments.
This new option specifically targets adults with primary hypercholesterolaemia or mixed dyslipidaemia – complex terms for conditions where the body produces too much "bad" LDL cholesterol. It's designed for people who haven't reached safe cholesterol levels despite taking the highest dose of statins they can tolerate, or those who simply can't take statins due to side effects. Given that high LDL cholesterol significantly increases the risk of heart attacks and strokes – and cardiovascular disease remains one of the UK's biggest killers – this represents a crucial breakthrough.
Statins have long been the gold standard for cholesterol management, and they work remarkably well for most people. However, around one in ten patients either don't respond adequately or experience troublesome side effects like muscle pain. Until now, these patients have had limited alternatives, leaving them at continued risk of potentially life-threatening cardiovascular events.
The new combination therapy works differently from statins, tackling cholesterol production in two ways: it reduces cholesterol manufacturing in the liver whilst also blocking its absorption in the gut. Clinical trials have shown impressive results, with significant reductions in LDL cholesterol levels that should translate into fewer heart attacks and strokes over time. This is particularly important given that cardiovascular disease accounts for approximately 25% of all deaths in the UK, with high cholesterol being one of the most treatable risk factors.
For patients, this approval means genuinely improved prospects – a lower chance of experiencing devastating cardiovascular events that can change lives forever. Whilst the treatment does represent an additional cost for the NHS, preventing heart attacks and strokes could ultimately save money by reducing expensive emergency care and long-term management of chronic conditions.
NHS England figures show that millions of adults across the UK are living with high cholesterol, with many cases going undiagnosed or inadequately treated. NICE's new guidance is expected to benefit thousands of high-risk patients who previously had few options beyond statins, offering them a realistic path to better health management. If you're struggling with cholesterol control, speak to your GP about whether this new treatment might be suitable for you.
Source: National Health Executive